Vrancx, Céline
Vadukul, Devkee M.
Suelves, Nuria
Contino, Sabrina
D’Auria, Ludovic
Perrin, Florian
van Pesch, Vincent
Hanseeuw, Bernard
Quinton, Loïc
Kienlen-Campard, Pascal http://orcid.org/0000-0003-1086-2942
Funding for this research was provided by:
Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture
Fonds De La Recherche Scientifique - FNRS (PDRT.0177.18)
SAO FRA Stop Alzheimer
Fondation Médicale Reine Elisabeth
Article History
Received: 27 May 2021
Accepted: 14 September 2021
First Online: 4 October 2021
Declarations
:
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: All animal experiments were performed with the approval of the UCLouvain Ethical Committee for Animal Welfare (Reference 2018/UCL/MD/011). Human cerebrospinal fluid samples were collected as part of clinical analyses performed at Cliniques Universitaires Saint-Luc (UCL, Brussels, Belgium).
: Symptomatic non-AD patients signed an internal regulatory document, stating that residual samples used for diagnostic procedures can be used for retrospective academic studies, without any additional informed consent (ethics committee approval: 2007/10SEP/233). AD patients participated to a specific study referenced UCL-2016–121 (Eudra-CT: 2018–003473-94).
: All authors have given consent for publication.